Successful Management of HFpEF-Related Pulmonary Hypertension With Systemic-Level Pressures Using Sacubitril-Valsartan and Empagliflozin
Abstract
BACKGROUND: Pulmonary hypertension (PH) is present in over two-thirds of patients who experience heart failure with preserved ejection fraction (HFpEF), and it worsens their prognosis, particularly when combined with right ventricular dysfunction. Effective treatments for HFpEF-related PH are limited.
CASE SUMMARY: A 70-year-old woman presented with severe exertional dyspnea and hypoxia. Echocardiography revealed a preserved ejection fraction with advanced diastolic dysfunction, as well as severe PH. Right heart catheterization showed pulmonary pressures at systemic levels and elevated left-sided filling pressures. Significant symptom improvement and normalized pulmonary pressures were noted after treatment with sacubitril-valsartan and a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
DISCUSSION: Although sacubitril-valsartan and SGLT2 inhibitors have been proven effective in HFpEF, their specific role in HFpEF-PH remains unclear. This case highlights their potential to improve hemodynamics and symptoms in this challenging patient population.
TAKE-HOME MESSAGE: Sacubitril-valsartan and SGLT2 inhibitors may be effective for treating PH in HFpEF; further investigation is warranted.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.